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tomy-decortication, and the local control for EPP is superior to that of 
the other modalities. 
Surgery And Multimodality Therapies
Combined Surgical Resection and Deﬁnitive Radiotherapy
After an EPP, radical radiotherapy can be administered without con-
cern for damage to the underlying ipsilateral lung because it has been 
removed surgically. However, radical radiotherapy after a pleurectomy 
continues to place the ipsilateral lung at risk for substantial loss of 
function. In a retrospective review of patients having P/D at Memorial 
Sloan-Kettering Cancer Center from 1974 to 2003 the data revealed that 
residual disease cannot be eradicated with external RT with or without 
brachytherapy and that a more extensive surgery followed by external 
RT might be required to improve local control and overall survival. 
Radiation therapy after EPP however, is beneﬁcial. Rusch completed a 
phase II trial of surgery followed by postoperative radiation in patients 
with pleural mesothelioma having EPP. The median survival was 17 
months, with an overall survival of 27% at 3 years. Only 13% had 
locoregional recurrence, with the majority of patients failing to respond 
and having distant metastases. 
IMRT also offers the potential for administering higher doses of radio-
therapy to the hemithorax while minimizing normal tissue toxicities. 
Recent data in 63 patients having EPP and IMRT reveals a median 
survival of 15 months for all patients, with patients having N0 status 
improving to 20 months compared to those with N1/N2 disease being 
11 months. Six patients experienced pulmonary complications leading 
to death which was attributable to the IMRT, usually at higher doses. 
These pulmonary complications have also been documented from the 
Dana Farber Cancer Institute. 
Pleurectomy/Intrapleural Chemotherapy ± Postoperative Chemo-
therapy
There has been interest in combining debulking surgery with intra-
cavitary treatment of pleural mesothelioma since the ﬁrst reports of 
intrapleural chemotherapy alone for malignant mesothelioma. The most 
recent trials of surgery and intrapleural chemotherapy have revealed an 
overall survival rate of 68% at 1 year and 44% at 2 years in the 27 pa-
tients who received the therapy, with a median survival of 17 months. 
Recurrences are chieﬂy locoregional. 
Extrapleural Pneumonectomy/Intravenous Chemotherapy and Postop-
erative Radiotherapy
A multimodal approach to malignant mesothelioma using EPP, postop-
erative chemotherapy, and targeted postoperative radiotherapy was the 
standard approach since 1980 at the Brigham and Women’s Hospital in 
Boston. Over a 19-year period, 183 patients have been treated with a 
perioperative mortality of 3.4%. The median survival in this group of 
patients is approximately 17 months, which was a signiﬁcant improve-
ment over other trials. This approach by the Boston Group has now 
been generally replaced with novel trials of intrapleural hyperthermic 
perfusion. 
Induction Chemotherapy followed by Surgery
With the improved efﬁcacy of doublet chemotherapy (gemcitabine/cis-
platin or pemetrexed/cisplatin), there is renewed interest in investigat-
ing a neoadjuvant approach for mesothelioma. A Swiss neoadjuvant 
study used three cycles of cisplatin and gemcitabine followed by EPP 
and RT to areas at risk. Of the 37 patients who had complete resec-
tion 36 received postoperative radiotherapy, and the mortality was 2%. 
Postoperative complications were observed in 62% and 2 patients died 
within 30 days (3.2%). For all patients, the one year survival was 69% 
with median survival of 18.4 months. For the 45 resected patients, 78% 
were alive at one year with a median survival of 26.3 months. Prelimi-
nary results of a multicenter North American trial of four cycles of 
pemetrexed and cisplatin followed by EPP and postoperative hemitho-
rax RT were presented at ASCO 2007. Of 77 patients initially enrolled, 
four cycles of chemotherapy could be delivered to 83% , but only 54/77 
had surgical exploration of which 47 had an EPP. Of these 47, 35 com-
pleted RT. Operative morality was 4%, and 1 year survival was 68%, 
with median survival of 16 months. 
Novel Intrapleural Approaches: New Techniques with New/Old Agents 
– Intrapleural Photodynamic Therapy
Photodynamic therapy (PDT) involves the light-activated sensitization 
of malignant cells using a photosensitizer, such as Photofrin II, which is 
retained by malignant tissue in vivo in comparison to normal tissue. Af-
ter a series of phase I and II trials, a group of 63 patients with localized 
mesothelioma were randomized to surgery, with or without intraopera-
tive PDT . There were no differences in median survival (14.4 vs. 14.1 
months) or median progression-free time (8.5 vs. 7.7 months), and 
sites of ﬁrst recurrence were similar. Other phase II trials of PDT and 
mesothelioma have not demonstrated limited therapeutic efﬁcacy, and 
results using intrapleural PDT with metaTetraHydroxyPhenylChlorin 
after EPP have revealed signiﬁcant toxicities without survival beneﬁt.
Pleural Perfusion
Hyperthermic chemoperfusion of the pleura after resection of meso-
thelioma is based on the hypothesis that the treatment will provide 
increased local control and avoid systemic chemotherapy toxicity. 
Sugarbaker has reported a phase I/II trial using hyperthermic cisplatin 
(42°C) to perfuse both the abdomen and the pleura after pleurec-
tomy/decortication. Operative mortality was 11%, and survival of all 
patients was 10.5 months; however, in the group of patients surviving 
surgery who received 225 mg/m2 of cisplatin, the median survival was 
22 months, and disease-free survival was 20 months. Further data with 
hyperthermic perfusion in patients having EPP are forthcoming. 
Conclusions
Despite safer surgery and new systemic therapies, median survival for 
mesothelioma patients having multimodality therapy is approximately 
24 months. Only through earlier recognition of the disease and discov-
ery of novel targets which will have satisfactory toxicity proﬁles can 
these median survivals be improved. 
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The incidence of malignant pleural mesothelioma (MPM) is increasing 
in many countries, and is expected to continue to rise for at least the 
next decade. The impacts of the disease include shortened life expec-
tancy, symptoms, and impairment of quality of life. For patients with 
early disease, aggressive multimodality therapy may improve out-
comes. However, the majority of patients who develop mesothelioma 
are not candidates for this type of approach, and will ultimately die of 
their disease. Therefore effective palliative treatments are required that 
can increase life span, minimize symptoms and improve quality of life. 
This presentation will focus on the development of systemic therapies 
for mesothelioma.
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Despite many clinical trials testing multiple cytotoxic agents, until 
recently, no systemic treatment had been shown to have an impact on 
survival or quality of life for patients with mesothelioma. The novel 
anti-folate agent pemetrexed was noted in early phase trials to result 
in tumour shrinkage in patients with mesothelioma. This led to a 
large scale randomised trial1 in which 226 patients were randomised 
to receive the combination of pemetrexed and cisplatin and 222 were 
treated with cisplatin alone. The combination led to an improvement 
in response rate (41% vs. 17%, p < 0.001), median survival (12.8 vs. 
9.0 months, p = 0.02 ) and 1 year survival (50% vs. 38%, p = 0.012). 
In addition, there was an improvement in symptoms and quality of life 
on the combination arm. These results were achieved with acceptable 
toxicity, particularly following the introduction of vitamin supplemen-
tation (now considered as standard when pemetrexed is given), with a 
febrile neutropenia rate of 1%, and no treatment related deaths. 
In a further randomised trial2, carried out by the EORTC, the combina-
tion of raltitrexed, another anti-folate, and cisplatin was compared to 
cisplatin alone. This was also a large study with a total of 250 patients 
randomised. The results of this trial were similar, with the combination 
yielding a non-signiﬁcantly improved response rate (24 % vs. 14%, p 
= 0.06), as well as better median (11.4 vs. 8.8 months, p = 0.048) and 
1 year survival (46% vs. 40%). Quality of life was also assessed in this 
study, and was similar in both study arms.
The results of these trials established the place of chemotherapy in the 
management of advanced pleural mesothelioma, with evidence that 
treatment resulted in prolongation of survival and stability or improve-
ment in symptoms and quality of life. However, critics of these trials 
correctly point out that cisplatin, the control arms in both of the studies, 
has never been shown to be better than no chemotherapy treatment 
at all in mesothelioma, and that neither of the studies contained an 
untreated control group. An ongoing British trial should help to address 
this point. In this study, patients with MPM are randomised to receive 
best supportive care alone, single agent chemotherapy with vinorelbine, 
or multi agent chemotherapy with cisplatin, vindesine and mitomy-
cin-C. The primary endpoint of the study is survival. At present, only 
feasibility data are available from a preliminary analysis, with ﬁnal 
efﬁcacy data awaited.
The well-described toxicities of cisplatin have also led to interest in 
the use of carboplatin in the treatment of MPM. Although no phase 3 
trials have been carried out with this agent, there are 3 published phase 
2 trials3-5 of the combination of carboplatin and pemetrexed. Results 
of these trials, which include a total of 205 patients, are broadly in 
keeping with those described above, with response rates ranging from 
20 - 30% and median survival ranging from 13 - 23 months. Treatment 
was associated with little toxicity. Whilst this combination has not been 
tested in a phase 3 trial, it would appear to be a viable alternative to the 
use of cisplatin and pemetrexed.
Another widely used regimen, tested only in phase 2 trials, is cisplatin 
and gemcitabine. The initial study of the use of this combination in 
MPM reported a response rate of 48%. There has been wide variation in 
subsequent reports, with response rates ranging from 9% to 26% in four 
other studies. It is difﬁcult to interpret these ﬁndings as patient selection 
factors almost certainly have played a role in the variability of results.
Although chemotherapy has been shown to improve outcomes for 
patients with MPM, the gains referred to above have been modest, and 
all patients ultimately die of their disease. Therefore investigation of 
newer treatment approaches remains important. The advent of a range 
of molecularly targeted therapies offers an opportunity to do this. Sev-
eral of these agents have already been evaluated in MPM, with studies 
ongoing using other agents.
Platelet derived growth factor (PDGF), is commonly expressed in 
MPM. To date, three trials using imatinib, an inhibitor of the PDGF 
tyrosine kinase, have been completed in patients with MPM. Unfortu-
nately, no responses were seen amongst the total of 71 patients included 
in these studies. Similarly, a study evaluating the epidermal growth fac-
tor receptor tyrosine kinase inhibitor geﬁtinib, demonstrated a response 
rate of only 4% suggesting inactivity of this agent in MPM. 
A more promising approach to the treatment of MPM may be to 
target the vascular endothelial growth factor (VEGF) or its receptor 
(VEGFR), which play a role in the process of angiogenesis. MPM is 
associated with high levels of VEGF, and high levels of VEGF are also 
a poor prognostic factor in the disease. Bevacizumab, an anti-VEGF 
monoclonal antibody has been studied in a randomised phase 2 study 
where it was added to chemotherapy (gemcitabine and cisplatin). To 
date, only toxicity data are available from this study, with bevacizumab 
adding little to toxicity other than hypertension and epistaxis. The ef-
ﬁcacy results from this study are awaited. 
Another anti-angiogenic agent that is undergoing evaluation in MPM 
is thalidomide. Two phase 2 studies, one from the Netherlands6, the 
other from Australia7, have suggested that thalidomide may produce 
prolonged disease stabilization following initial chemotherapy. In both 
these studies, approximately 25% of patients had stable disease for 6 
months or longer whilst being treated with thalidomide. As a result of 
these ﬁndings, coupled with the fact that the drug is well tolerated, it is 
now being evaluated in a randomised phase 3 trial where patients who 
do not progress during chemotherapy with pemetrexed with or without 
a platinum are randomised to maintenance thalidomide or no treatment. 
The primary endpoint of the study is progression free survival. 
Small molecule tyrosine kinase inhibitors of VEGFR are also being 
evaluated in MPM. These agents include vatalanib (a combined plate-
let-derived growth factor receptor and VEGFR inhibitor), pazopanib, 
and AZD2171. In a preliminary report, vatalanib has been demonstrated 
to produce a response rate of 11% amongst 47 patients with previously 
untreated MPM8. For the other two agents, studies are ongoing with 
limited efﬁcacy data available.
The treatment of advanced MPM remains a challenge despite the 
availability of agents that can impact on the disease. Trials that are 
currently underway should provide further information about the value 
of molecularly targeted agents that could potentlally have an impact on 
outcomes.
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